HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GMP Supplier Qualification Appears More Viable Route Than Testing

This article was originally published in The Tan Sheet

Executive Summary

While FDA allows supplement manufacturers to use "full testing" of ingredients as an alternative to the supplier qualification process, qualifying still appears to be the most viable and economical approach to GMP compliance

You may also be interested in...



Qualifying Suppliers For US Supplement Ingredient Identity Requirement Still An Option With Thorns

Failing to qualify suppliers “one of the more common citations” FDA inspectors find at supplement facilities, says ORA deputy director Michael Dutcher. “If you're not sort of reconfirming once in a while it could lead to a problem with your products that you weren't even expecting.”

In Covid-19 Storm, Supplement Manufacturers' Safe Harbor Could Be Qualifying New Suppliers

US manufacturers losing ingredient supplies from China may need to qualify more suppliers, potentially requiring tests of all lots, says EAS Consulting. Contract and other manufacturers also should identify alternative sources for materials they receive from China and prepare for shortages from other countries.

SIDI Group Expects "Passport" To Business Growth With Standardized CofA

Dietary supplement ingredient suppliers should approach standardizing information in their certificates of analysis as an investment that will pay off in business growth, say industry stakeholders who wrote a CofA guideline

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS135342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel